ReviewPLoS pathogens2020
The hallmarks of COVID-19 disease.
Review in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 246 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
246 citing papers in PubMed, 2 syntheses or guidelines pooled it, 480 citations in OpenAlex.
- Novel genes and sex differences in COVID-19 severity.Human molecular genetics · 2022Pooled it
- COVID-19 Pandemic Increases the Impact of Low Back Pain: A Systematic Review and Metanalysis.International journal of environmental research and public health · 2022Pooled it
- Assessment of a cellular host response test to risk-stratify suspected COVID-19 patients in the Emergency Department setting.PloS one · 2022Trial
- A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial.International immunopharmacology · 2021Trial
- Description and analysis of representative COVID-19 cases-A retrospective cohort study.PloS one · 2021Trial
- SARS-CoV-2 Effects on Respiratory and Neurological Systems: Morphological Findings and Gene Expression in K18-hACE2 Mice Model.Microorganisms · 2026Article
- A semantic FAIRness framework for epidemiological analysis of COVID-19 data in the UAE.Frontiers in public health · 2026Review
- Decoding the interplay between COVID-19 and diabetic nephropathy through bioinformatics and systems biology techniques.Biochemistry and biophysics reports · 2025Article
- Article
- The Etiopathogenesis of Kawasaki Disease: Evolving Understanding of Diverse Triggers.Immunity, inflammation and disease · 2025Review
- Monitoring SARS-CoV-2 Nsp13 helicase binding activity using expanded genetic code techniques.RSC chemical biology · 2025Article
- MMP-9 metalloproteinase and its regulator are not associated with mid-term CT residual abnormalities in patients with COVID-19 pneumonia.Acta radiologica open · 2025Article
- Pharmacological mechanism of action of Lianhua Qingwen in the treatment of COVID-19 and facial neuritis.World journal of otorhinolaryngology - head and neck surgery · 2025Article
- Investigating DNA damage caused by COVID-19 and influenza in post COVID-19.Mammalian genome : official journal of the International Mammalian Genome Society · 2025Article
- An explainable predictive machine learning model of gangrenous cholecystitis based on clinical data: a retrospective single center study.World journal of emergency surgery : WJES · 2025Article
- Impact of the COVID-19 pandemic on the volume and diagnoses of patients admitted to the paediatric emergency department: a retrospective analysis from a third-level hospital in Northeastern Mexico.BMJ public health · 2025Article
- The role of aryl hydrocarbon receptor signalling in COVID-19 pathology and its therapeutic potential.Frontiers in molecular medicine · 2025Review
- Immune aging and infectious diseases.Chinese medical journal · 2024Review
- A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation.Journal of virology · 2024Article
- All eyes on PCS: analysis of the retinal microvasculature in patients with post-COVID syndrome-study protocol of a 1 year prospective case-control study.European archives of psychiatry and clinical neuroscience · 2024Article
186 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel coronavirus that has caused a worldwide pandemic of the human respiratory illness COVID-19, resulting in a severe threat to public health and safety. Analysis of the genetic tree suggests that SARS-CoV-2 belongs to the same Betacoronavirus group as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Although the route for viral transmission remains a mystery, SARS-CoV-2 may have originated in an animal reservoir, likely that of bat. The clinical features of COVID-19, such as fever, cough, shortness of breath, and fatigue, are similar to those of many acute respiratory infections. There is currently no specific treatment for COVID-19, but antiviral therapy combined with supportive care is the main strategy. Here, we summarize recent progress in understanding the epidemiological, virological, and clinical characteristics of COVID-19 and discuss potential targets with existing drugs for the treatment of this emerging zoonotic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.